Anti-Melanoma Monoclonal Antibody 225.28S Immunoscintigraphy in Metastatic Melanoma

Abstract

Background: Accurate staging and early detection of metastases are crucial to melanoma management. It would thus be of great value to have a widely available, cost-effective method that allows to examine the whole body and is more specific than current imaging modalities. Objective: The purpose of the study was to assess the value of immunoscintigraphy with 99mTc-radiolabeled F(ab’)2 fragments of the 225.28S monoclonal antibody in the staging of melanoma. Methods: 29 patients with known or suspected metastases were enrolled in the study and examined by monoclonal antibody fragment scintigraphy. The results were compared to physical examination, other imaging modalities and, where available, histology. Results: Antibody scintigraphy detected 9/34 metastases. There were 2 false-positive lesions. Diagnostic accuracy was 41%, sensitivity 26% and specificity 83%. Conclusion: 99mTc-radiolabeled F(ab’)2 monoclonal antibody-fragment scintigraphy cannot be recommended for staging of melanoma patients. The search for more sensitive radiopharmaceuticals for scintigraphy should thus be encouraged.

Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4

“…Previous studies also showed that the anti-CSPG4 225.28 antibody with high affinity (1 × 10 −9 ) for CSPG4 49 , binds to a unique epitope on CSPG4 compared to other clones, and not to ubiquitously expressed carbohydrates 45,[50][51][52] . Furthermore, clone 225.28 has been safely introduced to melanoma patients, suggesting a low risk of off-target-related toxicities 53 for a 225.28-based treatment for melanoma.…”